Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Labs receives first ANDA for Merck's Timoptic under licensing agreement.

Executive Summary

ALCON GENERIC TIMOLOL APPROVED UNDER LICENSE FROM MERCK, the innovator of Timoptic ophthalmic solution for glaucoma. Alcon's timolol .25% and .5% ANDA was approved by FDA April 28 "based on a licensing agreement with the patent holder," FDA's Office of Generic Drugs reports in its April approval summary. Alcon's ANDA was tentatively approved by FDA in August 1994.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel